Endothelial Derived Hyperpolarization Factor and Vascular Control

Part of paid clinical trials in Norman, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT05176379
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 30 Years
Healthy Volunteers
Accepted

Interventions

  • Fluconazole 150 mg — DRUG
    A single acute 150 mg dose

Study Details

Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA

Key Dates

Start date
Feb 19, 2022
Status verified
Jul 2024
Primary completion
Dec 31, 2024
Completion
May 31, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: fluconazole
    fluconazole tablet/pill 150 mg, single acute dose
  • Placebo Comparator: Placebo
    250 mg pill microcrystalline Cellulose, single acute dose

Primary Outcome Measure

Near-Infrared Spectroscopy [ Time Frame: up to 4 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Department of Health and Exercise ScienceNormanOklahoma73019
Michael Bemben, PhD
[email protected]
405-325-5211
Jeremy M Kellawan, PhD
[email protected]
(405) 325-9028
Jeremy M Kellawan, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Norman, OK

By research site
Department of Health and Exercise Science· Norman, OK

Related Studies